Effect of sodium glucose cotransporter 2 inhibitor on liver function tests in Japanese patients with non-alcoholic fatty liver disease and type 2 diabetes mellitus

Hepatology Research

Volumn 47, Issue 10, 2017, Pages 1072-1078

  Seko, Yuya ^a   Sumida, Yoshio ^a   Tanaka, Saiyu ^b   Mori, Kojiroh ^b   Taketani, Hiroyoshi ^a   Ishiba, Hiroshi ^a   Hara, Tasuku ^a   Okajima, Akira ^a   Umemura, Atsushi ^a   Nishikawa, Taichiro ^a   Yamaguchi, Kanji ^a   Moriguchi, Michihisa ^a   Kanemasa, Kazuyuki ^b   Yasui, Kohichiroh ^a   Imai, Shunsuke ^b   Shimada, Keiji ^b   Itoh, Yoshito ^a  

^a KYOTO PREFECTURAL UNIVERSITY OF MEDICINE   (Japan)

^b Nara City Hospital   (Japan)

Author keywords

non alcoholic fatty liver disease; sodium glucose cotransporter 2 inhibitor; transient elastography; type 2 diabetes

Indexed keywords

AMINOTRANSFERASE; DIPEPTIDYL PEPTIDASE IV INHIBITOR; HEMOGLOBIN A1C; SODIUM GLUCOSE COTRANSPORTER 2 INHIBITOR;

ADULT; ARTICLE; BIOCHEMISTRY; BODY COMPOSITION; BODY MASS; BODY WEIGHT; CLINICAL ARTICLE; COMPARATIVE STUDY; CORRELATIONAL STUDY; DISEASE ASSOCIATION; DRUG EFFICACY; ENZYME ACTIVITY; FEMALE; GLUCOSE BLOOD LEVEL; HUMAN; HUMAN CELL; HUMAN TISSUE; JAPANESE (PEOPLE); LIVER FUNCTION TEST; MALE; MIDDLE AGED; NON INSULIN DEPENDENT DIABETES MELLITUS; NONALCOHOLIC FATTY LIVER; OUTCOME ASSESSMENT; PRIORITY JOURNAL; RETROSPECTIVE STUDY;

EID: 85008262665     PISSN: 13866346     EISSN: 1872034X     Source Type: Journal    
DOI: 10.1111/hepr.12834     Document Type: Article

References (17)

1. Promrat K, Kleiner DE, Niemeier HM et al. Randomized controlled trial testing the effects of weight loss on nonalcoholic steatohepatitis. Hepatology 2010; 51: 121–129.
2. Aguilar-Olivos NE, Almeda-Valdes P, Aguilar-Salinas CA et al. The role of bariatric surgery in the management of nonalcoholic fatty liver disease and metabolic syndrome. Metabolism 2016; 65: 1196–1207.
3. Adams LA, Crawford DH, Stuart K et al. The impact of phlebotomy in nonalcoholic fatty liver disease: a prospective, randomized, controlled trial. Hepatology 2015; 61: 1555–1564.
4. Promrat K, Lutchman G, Uwaifo GI et al. A pilot study of pioglitazone treatment for nonalcoholic steatohepatitis. Hepatology 2004; 39: 188–196.
5. Loomba R, Lutchman G, Kleiner DE et al. Clinical trial: pilot study of metformin for the treatment of non-alcoholic steatohepatitis. Aliment Pharmacol Ther 2009; 29: 172–182.
6. Iwasaki T, Yoneda M, Inamori M et al. Sitagliptin as a novel treatment agent for non-alcoholic fatty liver disease patients with type 2 diabetes mellitus. Hepatogastroenterology 2011; 58: 2103–2105.
7. Mashitani T, Noguchi R, Okura Y et al. Efficacy of alogliptin in preventing non-alcoholic fatty liver disease progression in patients with type 2 diabetes. Biomed Rep 2016; 4: 183–187.
8. Fukuhara T, Hyogo H, Ochi H et al. Efficacy and safety of sitagliptin for the treatment of nonalcoholic fatty liver disease with type 2 diabetes mellitus. Hepatogastroenterology 2014; 61(130): 323–328.
9. Honda Y, Imajo K, Kato T et al. The selective SGLT2 inhibitor ipragliflozin has a therapeutic effect on nonalcoholic steatohepatitis in mice. PLoS One 2016; 11: e0146337.
10. Nakano S, Katsuno K, Isaji M et al. Remogliflozin etabonate improves fatty liver disease in diet-induced obese male mice. J Clin Exp Hepatol 2015; 5: 190–198.
11. Qiang S, Nakatsu Y, Seno Y et al. Treatment with the SGLT2 inhibitor luseogliflozin improves nonalcoholic steatohepatitis in a rodent model with diabetes mellitus. Diabetol Metab Syndr 2015; 7: 104.
12. Brunt EM, Janney CG, Di Bisceglie AM et al. Nonalcoholic steatohepatitis: a proposal for grading and staging the histological lesions. Am J Gastroenterol 1999; 94: 2467–2474.
13. Kleiner DE, Brunt EM, Van Natta M et al. Design and validation of a histological scoring system for nonalcoholic fatty liver disease. Hepatology 2005; 41: 1313–1321.
14. Matteoni CA, Younossi ZM, Gramlich T et al. Nonalcoholic fatty liver diseases: a spectrum of clinical and pathological severity. Gastroenterology 1999; 116: 1413–1419.
15. Leiter LA, Forst T, Polidori D et al. Effect of canagliflozin on liver function tests in patients with type 2 diabetes. Diabetes Metab 2016; 42: 25–32.
16. Komiya C, Tsuchiya K, Shiba K et al. Ipragliflozin improves hepatic steatosis in obese mice and liver dysfunction in type 2 diabetic patients irrespective of body weight reduction. PLoS One 2016; 11: e0151511.
17. Yokono M, Takasu T, Hayashizaki Y et al. SGLT2 selective inhibitor ipragliflozin reduces body fat mass by increasing fatty acid oxidation in high-fat diet-induced obese rats. Eur J Pharmacol 2014; 727: 66–74.